DIGOXIN INJECTION C.S.D. LIQUID

Ország: Kanada

Nyelv: angol

Forrás: Health Canada

Aktív összetevők:

DIGOXIN

Beszerezhető a:

SANDOZ CANADA INCORPORATED

ATC-kód:

C01AA05

INN (nemzetközi neve):

DIGOXIN

Adagolás:

0.5MG

Gyógyszerészeti forma:

LIQUID

Összetétel:

DIGOXIN 0.5MG

Az alkalmazás módja:

INTRAMUSCULAR

db csomag:

10X2ML

Recept típusa:

Prescription

Terápiás terület:

CARDIOTONIC AGENTS

Termék összefoglaló:

Active ingredient group (AIG) number: 0107281002; AHFS:

Engedélyezési státusz:

APPROVED

Engedély dátuma:

2005-10-05

Termékjellemzők

<
D
IGOXIN INJECTION
C.S.D.
>
Page 1 of 42
Product Monograph
INCLUDING PATIENT MEDICATION INFORMATION
Pr
DIGOXIN INJECTION C.S.D.
Digoxin Injection
Liquid, 0.5 mg / 2 mL, Intramuscular, Intravenous
Manufacturer’s Standard
Cardiotonic Glycoside
Sandoz Canada Inc.
110 rue de Lauzon
Boucherville, QC, Canada
J4B 1E6
Date of Initial Authorization:
DEC 31, 1994
Date of Revision:
SEP 14, 2022
Submission Control Number: 262879
_ _
_ _
Page 2 of 42
RECENT MAJOR LABEL CHANGES
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
...........................................................................................
2
TABLE OF CONTENTS
.............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
4
1
INDICATIONS
..............................................................................................................
4
1.1
Pediatrics (<10 years of age)
................................................................................
4
1.2
Geriatrics (>70 years of age)
................................................................................
4
2
CONTRAINDICATIONS
.................................................................................................
4
4
DOSAGE AND ADMINISTRATION
.................................................................................
5
4.1
Dosing Considerations
.........................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
.................................................... 5
4.4
Administration
...................................................................................................
10
4.5
Missed Dose
..........................................................................................